PIK3CD correlates with prognosis, epithelial-mesenchymal transition and tumor immune infiltration in breast carcinoma

被引:6
作者
He, Wenxing [1 ]
Zhang, Haoyi [2 ]
Cheng, Hong [1 ]
Wen, Jianfeng [3 ]
Li, Dongmei [4 ,5 ]
机构
[1] Jiangxi Canc Hosp, Nanchang Med Coll, Breast Canc Ctr, 519 East Beijing Rd, Nanchang 330029, Peoples R China
[2] Nanchang Univ, Sch Publ Hlth, Nanchang 330006, Peoples R China
[3] Chinese Peoples Liberat Army, Hosp 908 Joint Support Force, Nanchang 330002, Peoples R China
[4] Jiangxi Canc Hosp, Nanchang Med Coll, Jiangxi Key Lab Translat Res Canc, 519 East Beijing Rd, Nanchang 330029, Jiangxi, Peoples R China
[5] Nanchang Cty Maternal & Child Hlth Hosp, Nanchang 330200, Peoples R China
关键词
Breast cancer; PIK3CD; CircRNA; Epithelial-mesenchymal transition; Prognosis; Tumor immune infiltration; GENE SIGNATURE;
D O I
10.1007/s12672-023-00805-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundBreast carcinoma (BRCA) is one of the most common, fatal, and aggressive cancers, with increasing morbidity that has a major impact on human health. PIK3CD appears to have important roles in the beginning and advancement of various forms of human cancer, according to mounting data. However,the particular role and mechanism of PIK3CD in BRCA remains not fully identified.MethodologyThe Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/), Genotype-Tissue Expression (GTEx) data and the UCSC Xena browser (https://xenabrowser.net) data were used in this study's initial pan-cancer analysis of PIK3CD expression and prognosis. Circular RNAs (circRNAs) that regulated the expression of PIK3CD were subsequently found using a combination of in silico investigations of expression, correlation, and survival. Measurements of PIK3CD expression and an analysis of the in vitro function of PIK3CD in BRCA cells were performed using real-time RT-PCR, Western blotting and Transwell assays.ResultsIn BRCA GLI2, RAB32, LAMB1, MGAT2, ITGA8, CHF, COL6A3 and PRRX1-miR-30b-5p axis was identified as the most likely upstream CircRNA-related route of PIK3CD. PIK3CD was correlated with the expression of EMT markers. The PIK3CD cDNA improved the capacity for invasion and migration. The expression of PIK3CD was linked to some of the m1A/m5C/m6A regulators. Additionally, it was discovered that the expression of PIK3CD was found to be highly connected to the expression of immunological checkpoints, immune cell biomarkers, and tumor immune cell invasion.ConclusionsOur findings reveal that PIK3CD expression is associated with prognosis, EMT, and tumor immune infiltration in BRCA patients.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] SYPL1 overexpression predicts poor prognosis of hepatocellular carcinoma and associates with epithelial-mesenchymal transition
    Chen, Dong-Han
    Wu, Qiu-Wan
    Li, Xiu-Dong
    Wang, Shuang-Jia
    Zhang, Zhi-Ming
    ONCOLOGY REPORTS, 2017, 38 (03) : 1533 - 1542
  • [32] Epithelial-Mesenchymal Transition Phenotype and Peritumoral Immune Cell Infiltration in Advanced Biliary Tract Cancer
    Oh, Chung Ryul
    Kim, Hyung-Don
    Ryu, Yeon-Mi
    Lee, Seonmin
    Kim, Danbee
    Lee, Da Sol
    Jeong, Jae Ho
    Chang, Heung-Moon
    Ryoo, Baek-Yeol
    Kim, Kyu-Pyo
    Kim, Miyeon
    Kim, Sang-Yeob
    Yoo, Changhoon
    ANTICANCER RESEARCH, 2023, 43 (02) : 645 - 652
  • [33] Upregulated FFAR4 correlates with the epithelial-mesenchymal transition and an unfavorable prognosis in human cholangiocarcinoma
    Meng, Fu-Tao
    Huang, Mei
    Shao, Feng
    Huang, Qiang
    CANCER BIOMARKERS, 2018, 23 (03) : 353 - 361
  • [34] Expression of pigment epithelium-derived factor is associated with a good prognosis and is correlated with epithelial-mesenchymal transition-related genes in infiltrating ductal breast carcinoma
    Zhou, Dan
    Zhang, Min
    Xu, Pengcheng
    Yu, Yang
    Ye, Guolin
    Zhang, Lin
    Wu, Aiguo
    ONCOLOGY LETTERS, 2016, 11 (01) : 116 - 124
  • [35] High tumor-associated macrophages infiltration is associated with poor prognosis and may contribute to the phenomenon of epithelial-mesenchymal transition in gastric cancer
    Yan, Yan
    Zhang, Jia
    Li, Jun-Hai
    Liu, Xu
    Wang, Ji-Zhao
    Qu, Hang-Ying
    Wang, Jian-Sheng
    Duan, Xiao-Yi
    ONCOTARGETS AND THERAPY, 2016, 9 : 3975 - 3983
  • [36] Clinically relevant morphological structures in breast cancer represent transcriptionally distinct tumor cell populations with varied degrees of epithelial-mesenchymal transition and CD44+CD24- stemness
    Denisov, Evgeny V.
    Skryabin, Nikolay A.
    Gerashchenko, Tatiana S.
    Tashireva, Lubov A.
    Wilhelm, Jochen
    Buldakov, Mikhail A.
    Sleptcov, Aleksei A.
    Lebedev, Igor N.
    Vtorushin, Sergey V.
    Zavyalova, Marina V.
    Cherdyntseva, Nadezhda V.
    Perelmuter, Vladimir M.
    ONCOTARGET, 2017, 8 (37) : 61163 - 61180
  • [37] Relationship of shear wave elastography anisotropy with tumor stem cells and epithelial-mesenchymal transition in breast cancer
    Xiaoling Leng
    Rexida Japaer
    Haijian Zhang
    Mila Yeerlan
    Fucheng Ma
    Jianbing Ding
    BMC Medical Imaging, 21
  • [38] Relationship of shear wave elastography anisotropy with tumor stem cells and epithelial-mesenchymal transition in breast cancer
    Leng, Xiaoling
    Japaer, Rexida
    Zhang, Haijian
    Yeerlan, Mila
    Ma, Fucheng
    Ding, Jianbing
    BMC MEDICAL IMAGING, 2021, 21 (01)
  • [39] Comprehensive proteome quantification reveals NgBR as a new regulator for epithelial-mesenchymal transition of breast tumor cells
    Zhao, Baofeng
    Xu, Bo
    Hu, Wenquan
    Song, Chunxia
    Wang, Fangjun
    Liu, Zhong
    Ye, Mingliang
    Zou, Hanfa
    Miao, Qing R.
    JOURNAL OF PROTEOMICS, 2015, 112 : 38 - 52
  • [40] Epithelial-mesenchymal transition classification of circulating tumor cells predicts clinical outcomes in progressive nasopharyngeal carcinoma
    Wei, Jiazhang
    Deng, Weiming
    Weng, Jingjin
    Li, Min
    Lan, Guiping
    Li, Xiang
    Ye, Linsong
    Wang, Yongli
    Liu, Fei
    Ou, Huashuang
    Wei, Yunzhong
    Huang, Wenlin
    Xie, Sifang
    Dong, Guohu
    Qu, Shenhong
    FRONTIERS IN ONCOLOGY, 2022, 12